Stanford Study Challenges Prevailing Views on the STING Pathway

For years, the STING (Stimulator of Interferon Genes) pathway has been at the center of efforts to harness the immune system’s natural defenses against cancer, with most research focused on activating this pathway to prompt immune cells to attack tumors. However, a new study published in Nature Chemical Biology and led by biochemist Lingyin Li is prompting a reassessment of this approach. The research highlights that while activating STING can help target cancer cells, too much activation may cause the immune system to attack healthy tissue, revealing a complex balance between activation and inhibition that has yet to be fully addressed in drug development.

The study examined H-151, a leading inhibitor of human STING. While H-151 had shown promise in reversing cognitive decline in mice, it failed to block human STING signaling in purified blood cells. “Our results show that in humans the target site of H-151 lacks a pocket that is found in mouse STING—without it, drug tailoring is incredibly challenging,” said Li. This structural difference explains why H-151 is effective in mice but not in humans, and underscores the limitations of relying on mouse models for developing STING-targeted therapies.

To address this gap, Li’s team investigated the key steps required for human STING signaling and identified oligomerization—the assembly of STING molecules—as a critical checkpoint before activation. Drawing on STING’s natural autoinhibitory mechanism, the researchers developed a proof-of-concept molecule that prevents this assembly, effectively blocking the pathway in human cells. “This work emphasizes the need to focus on developing STING inhibitors exclusively in humans,” said first author Xujun Cao. The findings open the door to new strategies for preventing STING-driven autoimmunity and may have future applications in neurodegeneration and autoimmune disease research.